Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FRESENIUS MEDICAL CARE AG & CO. KGAA

(FME)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

DGAP-PVR : Fresenius Medical Care AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

07/07/2021 | 06:02am EDT
DGAP Voting Rights Announcement: Fresenius Medical Care AG & Co. KGaA 
Fresenius Medical Care AG & Co. KGaA: Release according to Article 40, Section 1 of the WpHG [the German Securities 
Trading Act] with the objective of Europe-wide distribution 
2021-07-07 / 12:01 
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
Notification of Major Holdings 
1. Details of issuer 
 
 
 Name:                          Fresenius Medical Care AG & Co. KGaA 
 
 Street:                        Else-Kröner-Straße 1 
 
 Postal code:                   61352 
 
 City:                          Bad Homburg 
                                Germany 
 
 Legal Entity Identifier (LEI): 549300CP8NY40UP89Q40 
 2. Reason for notification 
 
 
 X             Acquisition/disposal of shares with voting rights 
 
               Acquisition/disposal of instruments 
 
               Change of breakdown of voting rights 
 
               Other reason: 
 3. Details of person subject to the notification obligation 
 
 
 Legal entity: Harris Associates L.P. 
 City of registered office, country: Wilmington, Delaware, United States of America (USA) 
 4. Names of shareholder(s) holding directly 3% or more voting rights, if different from 3. 
 
 
 Harris Associates Investment Trust 
 5. Date on which threshold was crossed or reached: 
 
 
 01 Jul 2021 
 6. Total positions 
 
 
                       % of voting rights % of voting rights through     Total of 
                       attached to shares                instruments    both in %        Total number of voting rights 
                          (total of 7.a.)   (total of 7.b.1 + 7.b.2)      (7.a. +             pursuant to Sec. 41 WpHG 
                                                                            7.b.) 
 
 New                               4.90 %                     0.00 %       4.90 %                          292,979,169 
 
 Previous                          5.15 %                     0.00 %       5.15 %                                    / 
 notification 
 7. Details on total positions a. Voting rights attached to shares (Sec. 33, 34 WpHG) 
 
 
 ISIN                    Absolute                        In % 
 
                       Direct       Indirect         Direct       Indirect 
               (Sec. 33 WpHG) (Sec. 34 WpHG) (Sec. 33 WpHG) (Sec. 34 WpHG) 
 
 DE0005785802               0     14,367,795         0.00 %         4.90 % 
 
 Total                  14,367,795                      4.90 % 
 b.1. Instruments according to Sec. 38 (1) no. 1 WpHG 
 
 
 Type of instrument Expiration or maturity date Exercise or conversion       Voting rights absolute Voting rights in % 
                                                period 
 
                                                                                                  0             0.00 % 
 
                                                Total                                             0             0.00 % 
 b.2. Instruments according to Sec. 38 (1) no. 2 WpHG 
 
 
 Type of        Expiration or maturity Exercise or conversion  Cash or physical            Voting rights  Voting rights 
 instrument     date                   period                  settlement                       absolute           in % 
 
                                                                                                       0         0.00 % 
 
                                                               Total                                   0         0.00 % 
 8. Information in relation to the person subject to the notification obligation 
 
 
 X             Person subject to the notification obligation is not controlled nor does it control any other 
               undertaking(s) that directly or indirectly hold(s) an interest in the (underlying) issuer (1.). 
 
               Full chain of controlled undertakings starting with the ultimate controlling natural person or legal 
               entity: 
 
 
 
 Name               % of voting rights (if at   % of voting rights through instruments (if  Total of both (if at least 
                            least 3% or more)                         at least 5% or more)                 5% or more) 
 
 
 9. In case of proxy voting according to Sec. 34 para. 3 WpHG (only in case of attribution of voting rights in accordance with Sec. 34 para. 1 sent. 1 No. 6 WpHG) Date of general meeting: Holding total positions after general meeting (6.) after annual general meeting: 
 
 
  Proportion of voting rights Proportion of instruments Total of both 
 
                            %                         %             % 
 10. Other explanatory remarks: 
 
 
 
 Date 
 
 
 06 Jul 2021 
 ----------------------------------------------------------------------------------------------------------------------- 

2021-07-07 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de -----------------------------------------------------------------------------------------------------------------------

Language:     English 
Company:      Fresenius Medical Care AG & Co. KGaA 
              Else-Kröner-Straße 1 
              61352 Bad Homburg 
              Germany 
Internet:     www.freseniusmedicalcare.com 
 
End of News   DGAP News Service 
=------------ 

1216210 2021-07-07

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1216210&application_name=news 
 

(END) Dow Jones Newswires

July 07, 2021 06:01 ET (10:01 GMT)

Stocks mentioned in the article
ChangeLast1st jan.
FRESENIUS MEDICAL CARE AG & CO. KGAA 0.10% 61.32 Delayed Quote.-10.09%
FRESENIUS SE & CO. KGAA -0.47% 41.12 Delayed Quote.8.67%
All news about FRESENIUS MEDICAL CARE AG & CO. KGAA
09/23European ADRs Move Sharply Higher in Thursday Trading
MT
09/23FRESENIUS MEDICAL CARE PUBLISHES 202 : Embracing the Complexity of Global Healthcare
PU
09/23FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section 1 of the W..
DJ
09/23FRESENIUS MEDICAL CARE AG & CO. KGAA : Release according to Article 40, Section 1 of the W..
EQ
09/22FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Buy rating from Berenberg
MD
09/22FMC FRESENIUS MEDICAL CARE AG & CO K : Goldman Sachs gives a Buy rating
MD
09/20FMC FRESENIUS MEDICAL CARE AG & CO K : Receives a Sell rating from Jefferies
MD
09/20PRESS RELEASE : Rentschler Biopharma appoints Dr. Christian Schetter as Chief Scientific O..
DJ
09/17FRESENIUS MEDICAL CARE : Selects JMS Co. as Distributor of Home Dialysis Systems in Japan
MT
09/17FMC FRESENIUS MEDICAL CARE AG & CO K : Sell rating from Jefferies
MD
More news
Analyst Recommendations on FRESENIUS MEDICAL CARE AG & CO. KGAA
More recommendations
Financials (USD)
Sales 2021 21 180 M - -
Net income 2021 1 274 M - -
Net Debt 2021 13 395 M - -
P/E ratio 2021 16,3x
Yield 2021 1,95%
Capitalization 21 052 M 21 037 M -
EV / Sales 2021 1,63x
EV / Sales 2022 1,53x
Nbr of Employees 123 538
Free-Float 67,8%
Chart FRESENIUS MEDICAL CARE AG & CO. KGAA
Duration : Period :
Fresenius Medical Care AG & Co. KGaA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FRESENIUS MEDICAL CARE AG & CO. KGAA
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Last Close Price 71,85 $
Average target price 80,61 $
Spread / Average Target 12,2%
EPS Revisions
Managers and Directors
Rice Powell Chief Executive Officer
Helen Giza Chief Financial Officer
Dieter Schenk Chairman-Supervisory Board
Olaf Schermeier CEO-Global Research & Development
Franklin W. Maddux Global Chief Medical Officer